GB0905570D0 - Combined vaccines - Google Patents

Combined vaccines

Info

Publication number
GB0905570D0
GB0905570D0 GBGB0905570.8A GB0905570A GB0905570D0 GB 0905570 D0 GB0905570 D0 GB 0905570D0 GB 0905570 A GB0905570 A GB 0905570A GB 0905570 D0 GB0905570 D0 GB 0905570D0
Authority
GB
United Kingdom
Prior art keywords
combined vaccines
vaccines
combined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0905570.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0905570.8A priority Critical patent/GB0905570D0/en
Publication of GB0905570D0 publication Critical patent/GB0905570D0/en
Priority to AU2009259006A priority patent/AU2009259006A1/en
Priority to JP2011513069A priority patent/JP2011522874A/ja
Priority to CN2009801230987A priority patent/CN102245203A/zh
Priority to US12/997,577 priority patent/US20110200635A1/en
Priority to KR1020117000394A priority patent/KR20110019417A/ko
Priority to CA2727322A priority patent/CA2727322A1/en
Priority to PCT/IB2009/006038 priority patent/WO2009150532A1/en
Priority to EP09762060A priority patent/EP2303321A1/en
Priority to US14/461,852 priority patent/US20140363468A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0905570.8A 2008-06-12 2009-03-31 Combined vaccines Ceased GB0905570D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0905570.8A GB0905570D0 (en) 2009-03-31 2009-03-31 Combined vaccines
EP09762060A EP2303321A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
US12/997,577 US20110200635A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
JP2011513069A JP2011522874A (ja) 2008-06-12 2009-06-12 季節性および汎流行性の防御のための混合インフルエンザワクチン
CN2009801230987A CN102245203A (zh) 2008-06-12 2009-06-12 用于季节性和大流行保护的联合流感疫苗
AU2009259006A AU2009259006A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
KR1020117000394A KR20110019417A (ko) 2008-06-12 2009-06-12 계절 및 유행성 보호를 위한 결합된 인플루엔자 백신
CA2727322A CA2727322A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
PCT/IB2009/006038 WO2009150532A1 (en) 2008-06-12 2009-06-12 Combined influenza vaccines for seasonal and pandemic protection
US14/461,852 US20140363468A1 (en) 2008-06-12 2014-08-18 Combined influenza vaccines for seasonal and pandemic protection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0905570.8A GB0905570D0 (en) 2009-03-31 2009-03-31 Combined vaccines

Publications (1)

Publication Number Publication Date
GB0905570D0 true GB0905570D0 (en) 2009-05-13

Family

ID=40672059

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0905570.8A Ceased GB0905570D0 (en) 2008-06-12 2009-03-31 Combined vaccines

Country Status (9)

Country Link
US (2) US20110200635A1 (cg-RX-API-DMAC7.html)
EP (1) EP2303321A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011522874A (cg-RX-API-DMAC7.html)
KR (1) KR20110019417A (cg-RX-API-DMAC7.html)
CN (1) CN102245203A (cg-RX-API-DMAC7.html)
AU (1) AU2009259006A1 (cg-RX-API-DMAC7.html)
CA (1) CA2727322A1 (cg-RX-API-DMAC7.html)
GB (1) GB0905570D0 (cg-RX-API-DMAC7.html)
WO (1) WO2009150532A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060430A2 (en) * 2008-11-28 2010-06-03 Statens Serum Institut Optimized influenza vaccines
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
ES2552383T3 (es) 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
CN102548577A (zh) * 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
CA2800182A1 (en) 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US20120219584A1 (en) * 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
JP5884100B2 (ja) * 2011-08-31 2016-03-15 公益財団法人東京都医学総合研究所 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
WO2013131898A1 (en) * 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
HK1215546A1 (zh) 2012-12-17 2016-09-02 Eurocine Vaccines Ab 鼻内接种疫苗给药方案
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3060247A1 (en) * 2013-10-25 2016-08-31 Leukocare Ag A novel method for the production of stabile vaccines
CN107847579A (zh) * 2014-12-19 2018-03-27 俄勒冈健康与科学大学 人和禽h5n1流感的计算优化的广泛反应性抗原的协同共同给药
WO2016104584A1 (ja) * 2014-12-25 2016-06-30 第一三共株式会社 皮内投与インフルエンザワクチン組成物
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
CN107151659B (zh) * 2017-03-01 2021-04-02 苏州系统医学研究所 一种流感病毒株及其应用
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
AU2018357917B2 (en) 2017-10-30 2024-08-01 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2019143955A1 (en) * 2018-01-22 2019-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly protective inactivated influenza virus vaccine
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1645283A1 (en) * 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
CA2602456A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
EP1951302A2 (en) * 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
AU2006310341B2 (en) * 2005-11-04 2011-01-06 Novartis Vaccines And Diagnostics Limited Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
WO2007144772A2 (en) * 2006-06-15 2007-12-21 Novartis Ag Adjuvant-sparing multi-dose influenza vaccination regimen
EP2497495B3 (en) * 2006-09-11 2021-02-17 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2121011B1 (en) * 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
TWI403518B (zh) * 2007-01-23 2013-08-01 Academia Sinica 一種流感疫苗及其使用方法
GB0810305D0 (en) * 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2227251A1 (en) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
AU2009227674C1 (en) * 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens

Also Published As

Publication number Publication date
CN102245203A (zh) 2011-11-16
US20110200635A1 (en) 2011-08-18
WO2009150532A1 (en) 2009-12-17
US20140363468A1 (en) 2014-12-11
CA2727322A1 (en) 2009-12-17
KR20110019417A (ko) 2011-02-25
JP2011522874A (ja) 2011-08-04
EP2303321A1 (en) 2011-04-06
AU2009259006A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
GB0905570D0 (en) Combined vaccines
ZA201109164B (en) Vaccine
IL211233A0 (en) Vaccine
IL208660A0 (en) Coccididosis vaccines
IL208651A0 (en) Vaccine
IL215962A0 (en) Soilid preparation
GB0822001D0 (en) Vaccine
GB201006165D0 (en) Vaccine
GB0810710D0 (en) Vaccine
ZA201007402B (en) Vaccine
GB0816284D0 (en) Vaccine
GB0907935D0 (en) Vaccines
GB0816447D0 (en) Vaccine
IL216102A0 (en) Combined measles-malaria vaccine
GB201000522D0 (en) Vaccine
GB0801326D0 (en) Vaccines
IL217194A0 (en) Vaccine
GB0909144D0 (en) Vaccines
GB0909145D0 (en) Vaccines
GB0909146D0 (en) Vaccines
GB0909147D0 (en) Vaccines
ZA201107971B (en) Combined measles-malaria vaccine
GB0914545D0 (en) Vaccine
GB0818459D0 (en) Vaccines
GB0907959D0 (en) Easy line-eyeliner

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)